Modelling and deciphering tumour metabolism in CRISPR screens

IF 66.8 1区医学 Q1 ONCOLOGY Nature Reviews Cancer Pub Date : 2024-10-01 DOI:10.1038/s41568-024-00758-8

Johannes Zuber, Wilhelm Palm

引用次数: 0

Abstract

Cell culture-based CRISPR screens have become instrumental in functionally annotating the human genome and identifying cancer dependencies. However, standard culture conditions poorly recapitulate the metabolic environments of tissues and organs. Modelling tumour-associated metabolic conditions opens new opportunities for cancer biology and therapeutic discovery. CRISPR screens in cell cultures reveal cancer dependencies yet often miss the metabolic nuances of tissues. In this Comment, Zuber and Palm highlight how modelling tumour-specific metabolic conditions can enhance our understanding of cancer biology and improve therapeutic discovery.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

在 CRISPR 筛选中模拟和解读肿瘤代谢。

基于细胞培养的CRISPR筛选已经成为功能性注释人类基因组和识别癌症依赖性的工具。然而，标准培养条件很难概括组织和器官的代谢环境。模拟肿瘤相关代谢条件为癌症生物学和治疗发现开辟了新的机会。细胞培养中的CRISPR筛选揭示了癌症依赖性，但往往忽略了组织代谢的细微差别。在这篇评论中，Zuber和Palm强调了肿瘤特异性代谢条件的建模如何增强我们对癌症生物学的理解并促进治疗发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nature Reviews Cancer 医学-肿瘤学

CiteScore

111.90

自引率

0.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Cancer, a part of the Nature Reviews portfolio of journals, aims to be the premier source of reviews and commentaries for the scientific communities it serves. The correct abbreviation for abstracting and indexing purposes is Nat. Rev. Cancer. The international standard serial numbers (ISSN) for Nature Reviews Cancer are 1474-175X (print) and 1474-1768 (online). Unlike other journals, Nature Reviews Cancer does not have an external editorial board. Instead, all editorial decisions are made by a team of full-time professional editors who are PhD-level scientists. The journal publishes Research Highlights, Comments, Reviews, and Perspectives relevant to cancer researchers, ensuring that the articles reach the widest possible audience due to their broad scope.

期刊最新文献

Metabolic vulnerability in fusion-driven ependymoma. Re-routing IgE for cancer therapy. Claudin proteins as emerging therapeutic targets for solid tumours. The intestinal microbiota as a key modulator of acute graft-versus-host disease. Decoding cancer across scales with metabolomics.